scholarly journals Editorial Comment from Dr Kobayashi to Pathological complete response after nivolumab therapy following angiogenesis inhibitors in a patient with metastatic renal cell carcinoma

2020 ◽  
Vol 3 (6) ◽  
pp. 292-292
Author(s):  
Takashi Kobayashi
2019 ◽  
Vol 2019 ◽  
pp. 1-4 ◽  
Author(s):  
An Uche ◽  
Chad Sila ◽  
Tad Tanoura ◽  
James Yeh ◽  
Neil Bhowmick ◽  
...  

Cabozantinib represents an established vascular endothelial growth factor- (VEGF-) tyrosine kinase inhibitor (TKI) in the treatment paradigm of metastatic renal cell carcinoma (mRCC). Its activity in mRCC patients with brain metastases (BMs) has been largely underreported in prospective clinical trials. We present the unique case of a heavily pretreated mRCC patient with BMs who achieved a brain complete response to cabozantinib prior to receiving radiation therapy. We end with a literature review and discussion of the biologic rationale and growing evidence supporting the intracranial activity of cabozantinib.


2016 ◽  
Vol 28 (5) ◽  
pp. 432-434 ◽  
Author(s):  
Beatrice Detti ◽  
Giulio Francolini ◽  
Carlotta Becherini ◽  
Emanuela Olmetto ◽  
Irene Giacomelli ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document